MDMA-Assisted CBCT for PTSD vs CBCT RCT
This interventional trial (n=60) aims to assess the efficacy and safety of MDMA-Assisted Cognitive-Behavioural Conjoint Therapy (CBCT) compared to CBCT alone in dyads where one member has Post-Traumatic Stress Disorder (PTSD).
Details
This randomized trial will compare MDMA-assisted CBCT to CBCT alone in 30 dyads (60 participants) over a 7-week psychotherapy course, using two MDMA-assisted therapy sessions as adjunctive treatment.
CBCT is a manualized dyadic PTSD treatment addressing symptoms and relationship functioning; the study will assess feasibility, safety, acceptability, and effectiveness relative to active comparator.
MDMA is hypothesised to enhance therapeutic engagement, empathy and communication, allowing deeper processing of traumatic memories when integrated into CBCT; CBCT-only participants may crossover to receive MDMA sessions after follow-up.